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INTRODUCTION 
The ultimate goal of tuberculosis (TB) control programs 
is the elimination of tuberculosis from society by 
stopping the transmission of TB infection, resulting in 
the disappearance of the disease. It can be best achieved 
through the identification and effective treatment of all 
contagious active cases, without creating at the same 
time resistance to the antibiotics used [l]. This has been 
shown in a number of communities which have 
developed such national TB programs. However, a 
recent review by WHO of the establishment of national 
programs around the world showed that only a 
minority of nations followed the international recorn- 
mendations, leading to only a slight decline in TB 
notifications [2]. Thus, even if treatment of active cases 
of TB remains the foundation for national policies to 
control its spread, it is still unknown whether this 
strategy will be sufficient to attain national goals for the 
elimination of TB. This strategy implies, first, a strong 
commitment by health authorities to give priority to 
TB within health planning, and, second, the recog- 
nition that this disease is a truly major health problem 
among persons in the economically productive years 
of life. Perceiving the full impact of TB is of major 
importance in establishing the strategy to fight it. 
Moreover, regular analyses of TB control measures have 
not usually examined the potential gains &om limiting 
the secondary spread of TB over consecutive years. 
Such long-term secondary spread could be reduced by 
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preventive measures (chernoprophylaxis and vaccina- 
tion). Nevertheless, the best preventive measures for 
TB in developing and industrialized nations are equally 
debatable. The major controversial features of the 
prevention methods are the use of isoniazid (INH) 
chemoprophylaxis in some industrialized and rich 
nations, particularly the USA, and the use of BCG 
vaccine in most of the developing nations. However, 
this dichiotorny does not only arise from the feasibility 
of establishing and carrying out such preventive 
measures, but is also associated with more profound 
pseudoscientific or dogmatic assertions opposing these 
control interventions. 
SHORT-TERM PROPHYLAXIS WITH 
ANTITUBERCULOUS CHEMOTHERAPY 
When thte INH regimen (300 mg daily for 12 months) 
is taken, the drug has been shown to be effective in 
preventing infection from progressing to active disease 
and in inhibiting recurrence of past disease [3] .  In the 
cited review, it was shown that INH was associated with 
an 88% reduction in aLI cases of evolving TB infection 
after 1 year, but such reduction was only 54% when 
evaluation was done 10 years later. However, the 
eacacy of chemoprophylaxis was directly related to the 
length of the course and to the compliance of the 
patients; the efficacy was 93% for patients with good 
compliance taking the drug for 12 months, but was 
reduced to 69% for patients with good compliance and 
taking the drug for 6 months. Such results and others 
[4,5] were used for recommendations for chemo- 
prophylaxis 25 years ago among tuberculin skin test 
converters in the USA [6]. The benefit-risk ratio has 
been clearly established for subgroups of high-risk 
tuberculin reactors: contacts of active TB cases, recent 
tuberculin converters, diabetics, silicotics, postgastrec- 
tomy patients, and patients under immunosuppressive 
therapy. All the published data from the literature 
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indicate the effectiveness of INH in treating early TB 
infection in immunocompetent and immunodepressed 
hosts and that progression to active TB should be 
preventable. Chemoprophylaxis, using a single agent 
such as INH at a relatively low dosing, has never been 
associated with any increased selection of INH 
resistance of TB bacilli. This might be due to the 
relatively small numbers of INH-susceptible bacilli 
present during TB infection and also to the normal 
capacity of the host to strengthen its acquired immune 
protection. 
Nevertheless, if one considers that more than 50% 
of newly diagnosed cases of TB are due to reactivation, 
this can be viewed as a failure of the prevention 
program. Also, prevention of TB by the use of INH is 
a multistep process and is a more complicated under- 
taking than simply prescribing a medication when it is 
indicated. Several steps are involved, and each of them 
presents problems. Individuals at risk for developing TB 
must be identified, must be offered INH,  and must 
accept it and take it in adequate amounts for an 
adequate length of time, and the drug must be effective 
in each specific case. One of the main difficulties of 
chemoprophylaxis may lie in the absence of an effective 
public-health system covering the whole population. 
Another may be the absence of screening for TB 
infection or, if screening is done, a failure to offer INH 
or poor compliance. A third deficiency may lie in the 
low sensitivity of the tuberculin s h n  test. 
If one considers the need for a well-functioning 
TB control program for the delivery of INH 
chemoprophylaxis, it is clear that INH prevention will 
not be feasible in most of the low-income countries. 
Thus, in 1991 the World Health Assembly recom- 
mended that a national TB program should achieve two 
main targets, in order to obtain a favorable impact on 
TB control: (1) to detect 70% of new sputum smear- 
positive cases, and (2) to treat successfully 85% of them 
[7]. There was no suggestion of contact tracing, or 
chemoprophylaxis [7]. Contact tracing has traditionally 
been recommended as a useful preventive measure, and 
a series of studies has indicated a high degree of adher- 
ence to established preventive guidelines a t  public- 
health clinics in the USA [8].  However, analysis of the 
potential failure of such preventive measures, made by 
Glassroth et a1 [9], showed that one third of the 279 TB 
cases studied had had no contact with healthcare 
professionals for at least 5 years before the development 
of TB. In one group of 64 individuals who had been 
recognized as contacts of potentially infectious persons, 
only half indicated having receiving a tuberculin test, 
and only eight were offered chemoprophylaxis. It is also 
reported that among another group of patients at risk 
of TB, a few received a skm test. In this group of 98 
patients who indicated either prior TB contact (64 
patients) or another risk factor (34 patients), only 11 
(1 1.2%) were offered chemoprophylaxis and 10 (90.9%) 
accepted it. From this particular study, one can observe 
that about 90% of individuals at risk were either not 
screened or not given chemoprophylaxis. Such failures 
need to be re-examined, since they indicate that health- 
care workers (HCWs) may not be well acquainted with 
current prevention guidelines. One of the limits of 
chemoprophylaxis is the perception of its benefit for 
the asymptomatic tuberculin converters. Chemo- 
prophylaxis of TB by giving INH to individuals whose 
only abnormality is a positive PPD skin test reaction 
suffers severely from imbalance between the low risk of 
TB, being diluted by its spread over a life-span, and the 
risk of treatment (hepatotoxicity) which may occur 
during the short period when medication is taken. It 
is, then, not surprising that some persons prefer to 
avoid immediate risk rather than distant threat of 
disease [lo]. It would appear desirable to concentrate 
on and publicize those aspects of TB prevention where 
a general agreement exists, and also to improve TB 
education in high-risk populations. 
The perception of the risk to HCWs themselves 
should be more acute and prevention more efficient. As 
indcated by several studies and in particular by the 
investigation of Sepkowitz [ l l ] ,  the current view of 
TB care as an occupational hazard emerged only in the 
late 1950s after a fierce and extensive debate. The 
resurgence of TB and above all the increased prevalence 
of multidrug-resistant (MDR) TB over the past decade 
has increased the perception of the risk of nosoconual 
transmission from patients to HCWs and several effec- 
tive infection control systems have been published [12]. 
However, there will always be some degree of occu- 
pational risk, and a mandatory comprehensive skin- 
testing program has been recommended by the CDC 
for all healthcare facilities as a part of TB infection 
control efforts [13]. A recent report from Emory 
University School of Medicine (Atlanta, USA) showed 
that when such a mandatory, comprehensive tuberculin 
skin-testing program was associated with physician 
referrals, the acceptance and completion of chemo- 
prophylaxis was very high [14] for all those with a 
positive tuberculin skin test. This contrasts with 
previous studies in which very poor physician com- 
pliance was reported with absence of a formal or 
mandatory tuberculin skin-testing program or estab- 
lished protocols for referrals at  many institutions for 
those with TB [15,16]. 
The tuberculin testing program cost was estimated 
at less than 10 US dollars per person, but it increased 
to 4500 dollars for a person eligible for chemo- 
prophylaxis with INH and to 350 000 dollars per case 
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of TB prevented, given the additional costs associated 
with investigation, treatment and follow-up [17]. 
Nevertheless, the CDC has proposed a policy of regular 
surveillance and tuberculin testing, depending on the 
level of risk. It seems that such recommendations will 
be more interesting in evaluating the short-term 
efficacy of the administrative measures needed to 
control the transmission of TB to HCWs than 
satisfactory in the long term for the individual HCW. 
In fact, adoption of such tuberculin skin-testing recom- 
mendations is still lacking for those in many institutions 
(such as long-term care), and in some hospitals [18]. It 
should be noted that the risk of tuberculin conversion 
among employees in an urban hospital may in some 
cases be unrelated to working conditions and associated 
instead with social and demographic factors [19]. In any 
case, the reaction to tuberculin is not just a simple 
correlate of infection by a member of the Mycobacterium 
tuberculosir complex, and epidemiologic information 
obtained with such testing will be reliable only if 
potential methodological problems are solved, 
including selection bias, the booster effect, differences 
in the antigen used for testing, the techniques of 
administration, and the interpretation of the results 
Chemoprophylaxis has been proposed as a strategy 
to control TB in the HIV-infected population [22]. 
HIV-positive patients with induration of 5 mm or more 
in reaction to five tuberculin units of PPD should be 
considered as having tuberculous infection and be 
offered chemoprophylaxis, if shown to be free of active 
TB. Treatment for 12 months is recommended. More- 
over, HIV-positive persons exposed to active cases of 
TB should be given chemoprophylaxis, regardless of 
the results of tuberculin testing. BCG should not be 
given to patients with AIDS, because of the possibility 
of their developing disseminated BCG infection. The 
benefit of chemoprophylaxis has been suggested by 
several observational studies in injecting drug users [23] 
and in the HIV populations of low-income countries 
[24,25]. However, a recent study of INH chemo- 
prophylaxis in HIV-positive anergic patients at high risk 
for TB did not show any benefit in comparison with 
the placebo group "261. A more accurate method of 
detecting latent tuberculosis than the old PPD skin test 
needs to be developed in order to identift people likely 
to benefit from prophylaxis. As jointly stated by WHO 
and the International Union Against Tuberculosis and 
Lung Disease (IUATLD) in 1993, the incorporation of 
chemoprophylaxis should only be considered in areas 
where national TB programs are achieving the targets 
established by WHO and where voluntary testing and 
counseling for HIV infection are available [27]. These 
statements emphasize that recommendations will 
[20,21]. 
depend on the setting and the target population. In 
countries where the annual risk of TB infection and the 
incidence of TB are low, chemoprophylaxis can be a 
standard medical practice in TB control. In low- 
income countries, where dual infection is common, 
and there is continuous exposure to active TB, while 
chemoprophylaxis might provide benefit to the 
individual patient, at least for a short period of time, 
there are no data on the effect on TB control. Both 
operational and efficacy trials are needed to further 
clarify the role of chemoprophylaxis in HIV-positive 
patients [28]. Although the frequency of INH-resistant 
and MDR TB has increased dramatically, especially 
among HIV-infected individuals, injecting drug users, 
homeless people and contacts of MDR TB (including 
HCWs) , there have been no controlled trials of altern- 
ative chernoprophylaxis regimens for the management 
of such individuals. In this situation, there is no con- 
sensus to give them chemoprophylaxis with more toxic 
and unproven new drugs 1291. 
LONG-TERM PROPHYLAXIS WITH VACCINATION 
Given the high costs and poor compliance associated 
with tiberculin testing and chemoprophylaxis with 
INH, combinations of alternative preventive measures 
have been devised by the use of mathematical models 
[30]. In Ithis work it has been shown that improvements 
in the coverage or effectiveness of treatment of 
diagnosed cases of TB are unhkely alone to achieve 
established national goals for elimination of TB. 
However, these goals can be achieved through a 
combination of improvements in current programs 
with targeted chemoprophylaxis and BCG vaccination. 
Although it has generally been accepted that 
BCG has no direct impact on the epidemiology of TB 
in low-prevalence countries 1311, the debate still 
continues about its potential value in selected risk 
groups [:32] and in HCWs [33]. Three decision analyses 
have been performed comparing BCG vaccination 
with tuberculin screening strategies [34-361. The first 
study [34] demonstrated that BCG vaccination would 
lead to fewer cases of TB among tuberculin-negative 
medical students and house officers over a 10-year 
period. BCG vaccine would require an efficacy rate 
of only 13.1% to prevent more cases of TB than 
tuberculin screening and INH chemoprophylaxis. The 
second study [35] showed that BCG vaccination would 
result in net cost-savings, in comparison with INH 
chernoprophylaxis, in persons attending shelters for the 
homeless, over a wide range of assumptions, but this 
conclusion was strongly dependent on the efficacy of 
the vaccine. The threshold for cost-savings was a 
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vaccine having an efficacy equal to or higher than 40%. 
In a high-risk transient population in which serial 
annual tuberculin testing and INH chemoprophylaxis 
would be fraught with difficulty, BCG vaccination 
policy needs to be reconsidered, in view of the alarm- 
ing increase in MDR TB and increased reports of TB 
in shelters in urban areas. The third report [36], which 
also concerned HCWs, favored the use of BCG for all 
assumed vaccine protective efficacies greater than 26% 
and the preference for BCG increased directly with 
increased efficacy, as reported in the two studies 
already discussed. This indicates that BCG should be 
considered for HCWs in an environment where a 
substantial risk of exposure to M D R  TB exists. BCG 
would increase its advantage with a decrease in the 
efficiency of detection of TB infection by tuberculin 
slun testing, with an increase in multiresistance rates 
and with a decrease in compliance with chemo- 
prophylaxis. The loss of the potential to use tuberculin 
slun testing in the diagnosis of TB infection after BCG 
vaccination has been claimed as a disadvantage by 
several epidemiologists, and the numerical analysis in 
this paper [35] included this potentially negative aspect 
of the use of BCG. 
The clear message from these studies is that BCG 
vaccination in persons exposed to TB or at risk of 
progressing from TB infection to disease should be 
reconsidered. However, BCG vaccination has not been 
recommended in the USA [37,38], because the overall 
efficacy of the vaccine in various trials has been 
variable, ranging from 0% to 80% [39] (see below) and 
because when given to adults the vaccine makes 
subsequent reactions to tuberculin uninterpretable, as 
discussed in two letters, by Miller and Castro [40] and 
by Reichman and Mangura [41]. 
Approximately 100 d i o n  newborns and children 
received the BCG vaccine in 1992, thanks to the 
organizational, financial and technical involvement of 
Expanded Programme for Immunization (EPI) [42]. 
Moreover, the BCG vaccine presents several advantages 
as compared with other vaccines: it can be given at 
birth or any time thereafter; a single inoculation can 
produce a long-lasting immune response; it is safe; it is 
relatively stable as a freeze-dried vaccine; it produces a 
scar, which is useful for epidemiologic surveillance; 
and it is inexpensive (from 0.02 to 0.5 US dollars). 
However, while its worldwide global immunization 
coverage in newborns was reported to be 85%, its 
efficacy remains a source of contention. Results from 
several controlled trials showing very high and very 
low vaccine efficacy have meant that there is little 
international agreement on the BCG vaccine [43]. A 
recent meta-analysis of selected trials concluded that 
BCG vaccination in infants and newborns is about 50% 
effective in preventing cases of pulmonary TB, but the 
data accepted for the review included those from trials 
recording much higher and lower protective efficacies 
[44]. It is still indicated in countries where the annual 
risk of infection during childhood is high. WHO [45], 
outlining problems and recommendations, noticed 
that the four major vaccine strains (Pasteur, Glaxo, 
Copenhagen, Tokyo) show great antigenic hetero- 
geneity and that numerous other strains are also in use 
which are not well characterized. At present there is no 
laboratory test available to demonstrate the protective 
efficacy of any particular antigenic mixture. Since it has 
not been possible to determine a threshold dose for any 
BCG vaccine, the rational procedure is to give the 
highest dose that is acceptable, acceptability being 
determined by the local vaccination reaction (ulcer, 
scar), and, in young children, by the incidence of 
suppurative axillary lymphadenitis. Thus, as suggested 
recently [46], variations in the BCG strain potency may 
have resulted from subtle pressures to minimize adverse 
reactions whde maintaining tuberculin reactivity, during 
vaccine development and testing. In fact, during the last 
prospective study carried out in Hong Kong (1978- 
86), it was shown that the Pasteur strain, known to be 
highly reactogenic, was better able to protect newborns 
than a less reactogenic Glaxo strain. Thus, quantitative 
differences between vaccines can be of practical 
importance [47]. WHO also states that vaccine efficacy 
appears highest among the youngest recipients and that 
BCG immunization does not prevent infection but 
limits initial spread of bacilli, as evidenced by animal 
experiments [48] and autopsy studies [49]. BCG 
vaccine appears much less effective in preventing 
primary complexes in the lungs (20% efficacy), primary 
complexes with local extension (32%) and lymph- 
adenitis (32%) than in preventing TB meningitis (52%) 
and disseminated TB (80%). The W H O  recommen- 
dations are to give one dose at birth, or at the first 
contact with the health service, and that there is no 
known advantage in giving a booster dose. Even if 
some studies indicated that BCG vaccine may be in fact 
more effective when given in the third month after 
birth, such studies did not evaluate protection, but only 
tuberculin conversion or scar production, which are by 
no means correlates for prevention [50]. The several 
cost-benefit analyses of BCG vaccination given in 
children concluded that the cost and benefit of BCG 
were almost equal where the average annual risk of 
TB infection did not exceed 0.1% [47]. Such analyses 
included only the direct individual protective effect, 
since it is believed that BCG has little impact on the 
overall transmission of the TB bacillus in the general 
population [31]. 
Most western European countries either have no 
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BCG policy or have a policy of vaccinating only high- 
risk children, revaccination being uncommon. Most 
eastern European countries vaccinate all infants at birth 
and revaccinate tuberculin-negative children at least 
once. However, there have been only a few evaluations 
of the efficacy of repeated BCG vaccination against TB. 
As stated by WHO recently, repeat vaccination is not 
supported by scientific evidence and is not recom- 
mended. Multiple revaccinations are not indicated in 
any person [51]. 
Another shortcoming of BCG vaccine is the 
absence of controlled trials to evaluate its ability to 
prevent TB in adults at risk, such as HCWs. Never- 
theless, a recent review of several published reports 
suggested that BCG vaccination is effective in reducing 
the incidence of TB in HCWs [33]. Despite the 
methodological flaws, the cohort studies indicate that 
rates of TB have been substantially lower (from 54% to 
85%) among HCWs receiving BCG vaccine than 
among unvaccinated HCWs with negative tuberculin 
skin tests. The data seem also to indicate that the 
vaccine efficacy increases with the risk of exposure to 
TB: the protection was greater in nurses in sanatoria 
than in all sanatoria employees or hospital-based 
student nurses. These observed results have not been 
generally accepted for two reasons: first, because of 
some inconsistencies in these old studies, and second, 
because BCG vaccination produces the same response 
to PPD as TB infection, thereby confusing and 
obscuring the diagnosis of recent infection [52]. 
Although, as already discussed, the efficacy of 
chemotherapy for tuberculin test converters in practice 
may be low [16], this remains a useful measure for 
protection of HCWs. The operational problems 
concerning such intervention are well characterized 
and could be easily solved [53]. This contrasts with the 
inconsistencies in BCG results that have long been the 
subject of debate without any consensus about the 
causes of variation. Bloom and Fine [54] believe that 
interference by environmental mycobacteria provides 
the best explanation for the observed results of BCG 
immunization, both in experimental studies and in the 
patterns of protection observed in different parts of 
the world. They suggest that other interfering factors 
(methodological flaws, heterogeneity between BCG 
vaccines, or M.  tuberculosic strains, genetic difference 
within and between populations, various capacity of 
BCG vaccines to protect against exogenous or end- 
ogenous infection) could play a role, but the evidence 
for these is not so convincing. 
One of the most important causes of the 
controversy about BCG vaccination may comprise the 
narrow viewpoints of some epidemiologists and health 
planning authorities, who concentrate on the immedi- 
ate (e.g. the annual reduction rate of TB infection, 
through the reduction of bacilli transmission) rather 
than on the long-term future (e.g. the long-term 
acquisition of a protective individual immunity). In this 
way, the varying reported resdts of the controlled trials, 
case-control studies and cohort studies have been 
utilized inappropriately as the exact intrinsic variability 
of the BCG vaccine potency in inducing acquired 
immunity against TB in a defined population (e.g. 
newborns, children, adults, HCWs). Yet, as for experi- 
mental models, the validity of any trial will depend 
upon the adequacy and accuracy of the endpoint 
measures of the model used. Since there is no simple 
in vitro or ex vivo measurable parameter of human 
acquirelcl immunity to TB, the o d y  measurable variable 
has been always the diagnosis of a TB case. The less 
accurate diagnosis will be then associated with the less 
accurate evaluation of differences between controls and 
vaccines. Such important methodological bias was 
emphasized several years ago by Clemens et a1 [55], 
who stated that ‘because the trials with the best 
methodological quality and greatest statistical precision 
reported high efficacy, the evidence suggests that BCG 
can confer a high degree of protection against TB, and 
that bias or inadequate statistical power may have 
contributed to the conflicting data’. Such bias and 
inadequate statistical power did not seem to have been 
taken into consideration, since several epidemiologists 
and health planning authorities continue to propagate 
the idea that variability in results is solely due to the 
variability of the BCG vaccine efficacy, instead of 
describing the relative factors involved among the 
reported trial results. As such, the observed variations 
mean thxt results of one trial cannot simply be extra- 
polated to other populations and conditions. Recently, 
the incursion of M D R  TB has led the Advisory 
Council for the Elimination of Tuberculosis and the 
Advisory Committee on Immunization Practices to 
recommend that BCG vaccination should be considered 
for HCWs, on an individual basis, when the local 
epidemiology of TB indicates that such workers have a 
high likelihood of exposure to M D R  TB and are not 
served by an effective infection control program [56]. 
Considering the chronic nature of TB, it may have 
been naive to expect BCG vaccination to protect 
against every form of TB [57]. By analogy, we have 
recently demonstrated that while BCG appeared able 
to protect with medium efficacy against leprosy in 
general, i n  fact its efficacy was only evident in unstable 
subpolar forms of leprosy, and not in the polar forms 
(lepromatous and tuberculoid) [58]. 
One of the big challenges for TB immunologists is 
to understand the physiopathologic mechanisms of the 
progressicin from infection to disease, and to detect the 
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underlying causative immunologic regulatory pathways 
that are associated with progression. The second task 
will be to analyze the possible interfering effect of BCG 
vaccination on such regulatory pathways, since BCG 
has been shown not to interfere with infection, but 
with disease progression [48,49]. Such fundamental 
approaches will give opportunities to select surrogate 
immunologic markers of induced protection and 
the factors that are able to downregulate it. In this way, 
the confounding effect of BCG vaccination on the 
tuberculin test may be eliminated. Until that time, the 
use of BCG vaccination will make questionable the 
usefulness of PPD testing for contact tracing. However, 
this situation also exists in individuals previously 
infected with atypical mycobacteria [53]. 
In a recent study [59], the authors stated that the 
age and infectivity of the index case, but not the BCG 
status in the contact, should be considered as key 
variables in the decision-malung process in the manage- 
ment of contacts. Moreover, available data suggest 
that disease-related hypersensitivity (PPD testing) and 
immunity (protection) are dissociable, giving us the 
prospect that it may be possible to induce immunity to 
infection without compromising the continued need 
for an ongoing system of immunodiagnosis. In con- 
clusion, in populations at  risk for TB, it is likely that a 
combination of immunodiagnosis, other modes of 
diagnosis, chemoprophylaxis and immunoprophylaxis 
will be required to eradicate the disease [60], as has 
been suggested by the computer simulations of TB 
control policies [30]. 
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